Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840658 | 1.00 | ATR (0.52) | ATRCCR2PTGER1GSK3AMAPK10 | |
| Ethoxycarbonyl Group SCHEMBL28328768 | 0.88 | ATR (0.43) | ATRCCR2PTGER1GSK3AMAPK10 | |
| SCHEMBL14692716 | 0.85 | GAA (0.46) | ATRCCR2PTGER1GSK3AMAPK10 | |
| SCHEMBL16926556 | 0.84 | JAK2 (0.58) | GSK3AMAPK10RIOK2JAK2JAK1 | |
| SCHEMBL1192656 | 0.83 | ATR (0.50) | ATRCCR2JAK2JAK1TYK2 | |
| SCHEMBL828560 | 0.83 | TP53 (0.51) | MAPK10MAPT | |
| SCHEMBL30953487 | 0.83 | ATR (0.50) | ATRCCR2JAK2JAK1TYK2 | |
| SCHEMBL21394568 | 0.82 | CCR2 (0.50) | ATRCCR2PTGER1JAK2JAK1 | |
| SCHEMBL29358615 | 0.82 | CCR2 (0.50) | ATRCCR2PTGER1JAK2JAK1 | |
| SCHEMBL29442824 | 0.82 | CCR2 (0.50) | ATRCCR2PTGER1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727435-B1 | BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR | UNIV CARNEGIE MELLON (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-29 | — | — | US | disclosed |
| CN-115515685-B | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4479397-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG Pharmaceutical Co., Ltd. (KR) | 2024-12-25 | — | — | EP | disclosed |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-119032087-A | Pyrimidinedione-based compounds as AXL, C-MET and MER inhibitors and methods of use thereof | CMG制药株式会社 | 2024-11-26 | — | — | CN | disclosed |
| CN-107922387-B | Heterocyclic inhibitors of ERK1 and ERK2 and their use in cancer treatment | 阿沙纳生物科学公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| CN-1478078-A | Nitrogen-containing aromatic ring derivatives | ������������ʽ���� | 2004-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | ATR 3205/4885CCR2 278/4885PTGER1 1391/4885 |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, RET | ATR 426/4885CCR2 1297/4885PTGER1 3910/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ATR 2342/4885CCR2 4209/4885PTGER1 4670/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | ATR 580/4885CCR2 1513/4885PTGER1 2740/4885 |
| US-12186324-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | ATR 1400/4885CCR2 1293/4885PTGER1 2251/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | ATR 4577/4885CCR2 489/4885PTGER1 662/4885 |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | MERTK, AXL, MET | ATR 454/4885CCR2 1351/4885PTGER1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.